Paradigm shift in chemotherapy administration disrupting the port market


Targeting a $1B market with a simple solution and leveraging existing reimbursement, Portal is designed to expand the use of ports with a simple solution performed in oncology clinics.  Applying a robust IP portfolio of patents covering methods and device, the experienced team has a proven track record of 6 successful exits with acquisitions by Medtronic, BD, Guerbet, Merit, ICU, Sebela.